Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the cognitive functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry
Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…Carrier mediated delivery system bearing dopamine for effective management of parkinsonism
Objective: In the present investigation, amino acid coupled liposome bearing dopamine-HCl were prepared to deliver drug to the brain utilizing receptor-mediated transcytosis for effective management…Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the cognitive functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of Pramipexole (PPX). Background: Parkinson's disease (PD) is characterized by both motor…Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease
Objective: Evaluate the efficacy and dosing of IPX066 in patient groups taking concomitant Parkinson's disease (PD) medication, using post hoc subgroup analyses. Background: IPX066 is…Higher doses of dopamine agonists, impulse control disorders and history of deep brain stimulation (DBS): Risk factors for dopamine agonists withdrawal syndrome (DAWS)?
Objective: To identify risk factors in the development of DAWS in patients with Parkinson's disease (PD). Background: DAWS is often a severe, stereotyped cluster of…Clinical characterization of pramipexole induced edema in Parkinson’s disease (PD). Is it always the best option discontinue the treatment?
Objective: Report a patient with PD treated with irregular doses of pramipexole and extensive chronic edema in lower extremities after 8 years of treatment, taking…Medication use patterns vary across expert Parkinson’s disease clinics
Objective: This analysis aims to describe and quantify the medication patterns for patients with Parkinson's disease (PD) managed in expert clinics. Background: Antiparkinson medication use…Dophaminergic therapy and its influence on the olfactory function of patients with Parkinson’s disease
Objective: The aim of this study was to investigate effects of dophaminergic therapy on olfaction of patients with Parkinson's disease. Background: Influence of dopaminergic drugs…May early introduction of dopaminergic agonists improve simptoms after ischemic stroke? The interim report
Objective: To evaluate the effect of bromocriptine on motor impairment, functional disabilit and cognitive impairment 5, 10, and 15 of bromocriptine therapy in patients with…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.